{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:20:19Z","timestamp":1787314819983,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Direct-acting Antiviral Agents (DAAs) influence serum lipids of patients with Hepatitis C virus (HCV). This paper presents an analysis of the relevant literature to investigate the effects of DAAs in treating hepatitis C to achieve a sustained viral response (SVR) on lipid parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed,Web of science, Embase and Central databases were searched, with a deadline of September 2023. Studies on the effects of sustained viral response on lipid parameters after DAAs treatment for hepatitis C were selected. The required information was extracted from the included studies, and then the Stata 12.0 was used to analyze the data quantitatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 32 studies, the results showed that total cholesterol (TC) levels increased from the end of treatment (WMD = 20.144, 95%CI = 3.404, 36.884,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.018) to one year after treatment (WMD = 24.900, 95%CI = 13.669, 36.131,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). From the end of treatment (WMD = 17.728, 95%CI = 4.375, 31.082,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.009) to one year after treatment (WMD = 18.528, 95%CI = 7.622, 29.433,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), the levels of low-density lipoprotein (LDL) were also increased. High-density lipoprotein (HDL) levels were elevated from 4 weeks after treatment (WMD = 6.665, 95%CI = 3.906, 9.424,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) to 24 weeks after treatment (WMD = 3.159,95% CI = 0.176, 6.142,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.038). Triglyceride (TG) levels showed no significant change after the treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hepatitis C patients who achieved SVR on DAAs showed the increase of lipid levels and the improvement of hepatic inflammation indicators AST and ALT. This may provide evidence-based medical evidence for the follow-up and monitoring of blood lipids and hyperlipidemia treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42020180793.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-023-01957-2","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T10:01:31Z","timestamp":1709978491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Tingting","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"issue":"1","key":"1957_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1042\/BC20090125","volume":"102","author":"CI Popescu","year":"2009","unstructured":"Popescu CI, Dubuisson J. Role of lipid metabolism in Hepatitis C virus assembly and entry[J]. Biol Cell. 2009;102(1):63\u201374.","journal-title":"Biol Cell"},{"key":"1957_CR2","unstructured":"Hepatitis C. WHO https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"issue":"5","key":"1957_CR3","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/v5051292","volume":"5","author":"DJ Felmlee","year":"2013","unstructured":"Felmlee DJ, Hafirassou ML, Lefevre M, et al. Hepatitis C virus, cholesterol and lipoproteins\u2013impact for the viral life cycle and pathogenesis of Liver disease[J]. Viruses. 2013;5(5):1292\u2013324.","journal-title":"Viruses"},{"issue":"5","key":"1957_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ijantimicag.2018.11.024","volume":"53","author":"S Lanini","year":"2019","unstructured":"Lanini S, Scognamiglio P, Pisapia R, et al. Recovery of metabolic impairment in patients who cleared chronic Hepatitis C Infection after direct-acting antiviral therapy[J]. Int J Antimicrob Agents. 2019;53(5):559\u201363.","journal-title":"Int J Antimicrob Agents"},{"key":"1957_CR5","doi-asserted-by":"crossref","unstructured":"Graf C, Welzel T, Bogdanou D et al. Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid Homeostasis[J]. J Clin Med, 2020,9(9).","DOI":"10.3390\/jcm9092702"},{"key":"1957_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2893.2005.00669.x","volume":"13","author":"A Lonardo","year":"2006","unstructured":"Lonardo A, Loria P, Adinolfi LE, et al. Hepatitis C and steatosis: a reappraisal [J]. J Viral Hepat. 2006;13:73\u201380.","journal-title":"J Viral Hepat"},{"issue":"3","key":"1957_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0168-8278(00)00036-2","volume":"34","author":"L Serfaty","year":"2001","unstructured":"Serfaty L, Andreani T, Giral P, et al. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic Hepatitis C[J]. J Hepatol. 2001;34(3):428\u201334.","journal-title":"J Hepatol"},{"issue":"6","key":"1957_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli A, Shaffer A, Sherman A, et al. Treatment of Hepatitis C: a systematic review[J]. JAMA. 2014;312(6):631\u201340.","journal-title":"JAMA"},{"issue":"5","key":"1957_CR9","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","volume":"146","author":"JM Pawlotsky","year":"2014","unstructured":"Pawlotsky JM. New Hepatitis C therapies: the toolbox, strategies, and challenges[J]. Gastroenterology. 2014;146(5):1176\u201392.","journal-title":"Gastroenterology"},{"issue":"9","key":"1957_CR10","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/jvh.13543","volume":"28","author":"SA McDonald","year":"2021","unstructured":"McDonald SA, Barclay ST, Innes HA, et al. Uptake of interferon-free DAA therapy among HCV-infected decompensated Cirrhosis patients and evidence for decreased mortality[J]. J Viral Hepat. 2021;28(9):1246\u201355.","journal-title":"J Viral Hepat"},{"issue":"11","key":"1957_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/hepr.13709","volume":"51","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Shinkawa H, Tamori A, et al. Postoperative direct-acting antiviral treatment after liver resection in patients with Hepatitis C virus-related hepatocellular carcinoma[J]. Hepatol Re. 2021;51(11):1102\u201314.","journal-title":"Hepatol Re"},{"key":"1957_CR12","doi-asserted-by":"publisher","first-page":"678546","DOI":"10.3389\/fphar.2021.678546","volume":"12","author":"H Roguljic","year":"2021","unstructured":"Roguljic H, Nincevic V, Bojanic K, et al. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: an Update[J]. Front Pharmacol. 2021;12:678546.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1957_CR13","doi-asserted-by":"publisher","first-page":"e209615","DOI":"10.1371\/journal.pone.0209615","volume":"13","author":"N Kawagishi","year":"2018","unstructured":"Kawagishi N, Suda G, Nakamura A, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis[J]. PLoS ONE. 2018;13(12):e209615.","journal-title":"PLoS ONE"},{"issue":"46","key":"1957_CR14","doi-asserted-by":"publisher","first-page":"10226","DOI":"10.3748\/wjg.v22.i46.10226","volume":"22","author":"MR Pedersen","year":"2016","unstructured":"Pedersen MR, Patel A, Backstedt D, et al. Genotype specific peripheral lipid profile changes with Hepatitis C therapy[J]. World J Gastroenterol. 2016;22(46):10226\u201331.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"1957_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790\u20139.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"1","key":"1957_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12664-019-00935-w","volume":"38","author":"A Jain","year":"2019","unstructured":"Jain A, Kalra BS, Srivastava S, et al. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic Hepatitis C, genotype 3 patients[J]. Indian J Gastroenterol. 2019;38(1):39\u201343.","journal-title":"Indian J Gastroenterol"},{"issue":"3","key":"1957_CR17","first-page":"156","volume":"10","author":"T Ichikawa","year":"2019","unstructured":"Ichikawa T, Miyaaki H, Miuma S, et al. Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV Infection receiving Daclatasvir\/Asunaprevir[J]. Biomed Rep. 2019;10(3):156\u201364.","journal-title":"Biomed Rep"},{"issue":"9","key":"1957_CR18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2169\/internalmedicine.1514-18","volume":"58","author":"T Ichikawa","year":"2019","unstructured":"Ichikawa T, Miyaaki H, Miuma S, et al. Carotid intima-media thickness and small dense low-density lipoprotein cholesterol increase after one year of treatment with direct-acting antivirals in patients with Hepatitis C Virus Infection[J]. Intern Med. 2019;58(9):1209\u201315.","journal-title":"Intern Med"},{"issue":"5","key":"1957_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jfma.2018.09.016","volume":"118","author":"PN Cheng","year":"2019","unstructured":"Cheng PN, Chiu YC, Chien SC, et al. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without Ribavirin for genotype 2 chronic Hepatitis C in Taiwan[J]. J Formos Med Assoc. 2019;118(5):907\u201313.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1957_CR20","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41598-018-37829-4","volume":"9","author":"PN Cheng","year":"2019","unstructured":"Cheng PN, Chen JY, Chiu YC, et al. Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients[J]. Sci Rep. 2019;9(1):1426.","journal-title":"Sci Rep"},{"key":"1957_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinbiochem.2018.07.007","volume":"60","author":"GS Lacerda","year":"2018","unstructured":"Lacerda GS, Medeiros T, Rosario N, et al. Exploring lipid and apolipoprotein levels in chronic Hepatitis C patients according to their response to antiviral treatment[J]. Clin Biochem. 2018;60:17\u201323.","journal-title":"Clin Biochem"},{"issue":"3","key":"1957_CR22","doi-asserted-by":"publisher","first-page":"E203","DOI":"10.1111\/hepr.12970","volume":"48","author":"T Inoue","year":"2018","unstructured":"Inoue T, Goto T, Iio E, et al. Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with Hepatitis C virus[J]. Hepatol Res. 2018;48(3):E203\u201312.","journal-title":"Hepatol Res"},{"issue":"1","key":"1957_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","volume":"17","author":"S Gitto","year":"2018","unstructured":"Gitto S, Cicero A, Loggi E, et al. Worsening of serum lipid Profile after Direct Acting Antiviral Treatment[J]. Ann Hepatol. 2018;17(1):64\u201375.","journal-title":"Ann Hepatol"},{"issue":"1","key":"1957_CR24","doi-asserted-by":"publisher","first-page":"1435124","DOI":"10.1080\/19932820.2018.1435124","volume":"13","author":"SG El","year":"2018","unstructured":"El SG, Soliman E, Ahmad A, et al. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic Hepatitis C genotype 4 in the era of DAAs[J]. Libyan J Med. 2018;13(1):1435124.","journal-title":"Libyan J Med"},{"issue":"2","key":"1957_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5009\/gnl17179","volume":"12","author":"T Chida","year":"2018","unstructured":"Chida T, Kawata K, Ohta K, et al. Rapid Changes in serum lipid profiles during combination therapy with Daclatasvir and asunaprevir in patients infected with Hepatitis C Virus genotype 1b[J]. Gut Liver. 2018;12(2):201\u20137.","journal-title":"Gut Liver"},{"issue":"2","key":"1957_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1590\/s0004-2803.201800000-33","volume":"55","author":"VG Andrade","year":"2018","unstructured":"Andrade VG, Yamashiro F, Oliveira CV, et al. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?[J]. Arq Gastroenterol. 2018;55(2):184\u20137.","journal-title":"Arq Gastroenterol"},{"issue":"4","key":"1957_CR27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/00325481.2017.1311197","volume":"129","author":"R Juanbeltz","year":"2017","unstructured":"Juanbeltz R, Goni ES, Uriz-Otano JI, et al. Safety of oral direct acting antiviral regimens for chronic Hepatitis C in real life conditions[J]. Postgrad Med. 2017;129(4):476\u201383.","journal-title":"Postgrad Med"},{"issue":"13","key":"1957_CR28","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.3748\/wjg.v23.i13.2355","volume":"23","author":"D Endo","year":"2017","unstructured":"Endo D, Satoh K, Shimada N, et al. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic Hepatitis C genotype 1b[J]. World J Gastroenterol. 2017;23(13):2355\u201364.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1957_CR29","doi-asserted-by":"publisher","first-page":"7845","DOI":"10.1038\/s41598-018-26293-9","volume":"8","author":"K Shimizu","year":"2018","unstructured":"Shimizu K, Soroida Y, Sato M, et al. Eradication of Hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter[J]. Sci Rep. 2018;8(1):7845.","journal-title":"Sci Rep"},{"issue":"8","key":"1957_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/lt.25060","volume":"24","author":"J Beig","year":"2018","unstructured":"Beig J, Orr D, Harrison B, et al. Hepatitis C Virus Eradication with New Interferon-Free Treatment improves metabolic Profile in Hepatitis C virus-related liver transplant Recipients[J]. Liver Transpl. 2018;24(8):1031\u20139.","journal-title":"Liver Transpl"},{"issue":"7","key":"1957_CR31","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/gutjnl-2017-313832","volume":"67","author":"HY Sun","year":"2018","unstructured":"Sun HY, Cheng PN, Tseng CY, et al. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir\/elbasvir or ledipasvir\/sofosbuvir treatment against chronic HCV infection[J]. Gut. 2018;67(7):1342\u201350.","journal-title":"Gut"},{"issue":"44","key":"1957_CR32","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.3748\/wjg.v25.i44.6551","volume":"25","author":"Y Yang","year":"2019","unstructured":"Yang Y, Wu FP, Wang WJ, et al. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with Hepatitis C virus genotypes 1, 2 and 3 in northwest China[J]. World J Gastroenterol. 2019;25(44):6551\u201360.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"1957_CR33","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.14309\/ctg.0000000000000203","volume":"11","author":"R Munoz-Hernandez","year":"2020","unstructured":"Munoz-Hernandez R, Ampuero J, Millan R, et al. Hepatitis C Virus Clearance by Direct-Acting antivirals agents improves endothelial dysfunction and subclinical Atherosclerosis: HEPCAR Study[J]. Clin Transl Gastroenterol. 2020;11(8):e203.","journal-title":"Clin Transl Gastroenterol"},{"issue":"7","key":"1957_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.medcli.2020.04.050","volume":"156","author":"M Sangineto","year":"2021","unstructured":"Sangineto M, Luglio CV, Mastrofilippo T, et al. Analysis of hepatic stiffness after viral eradication in a population with chronic Hepatitis C treated with DAAs[J]. Med Clin (Barc). 2021;156(7):317\u201323.","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"1957_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2169\/internalmedicine.7172-21","volume":"61","author":"S Inomata","year":"2022","unstructured":"Inomata S, Morihara D, Anan A, et al. Male-specific association between Iron and lipid metabolism changes and Erythroferrone after Hepatitis C Virus Eradication[J]. Intern Med. 2022;61(4):461\u20137.","journal-title":"Intern Med"},{"issue":"1","key":"1957_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/jvh.13406","volume":"28","author":"JY Chen","year":"2021","unstructured":"Chen JY, Cheng PN, Chiu YC, et al. Persistent augmentation of central arterial stiffness following viral clearance by direct-acting antivirals in chronic Hepatitis C[J]. J Viral Hepat. 2021;28(1):159\u201367.","journal-title":"J Viral Hepat"},{"issue":"1","key":"1957_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21037\/atm-20-669","volume":"9","author":"D Iossa","year":"2021","unstructured":"Iossa D, Vitrone M, Gagliardi M, et al. Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment[J]. Ann Transl Med. 2021;9(1):35.","journal-title":"Ann Transl Med"},{"issue":"1","key":"1957_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/17474124.2020.1823831","volume":"15","author":"R Eletreby","year":"2021","unstructured":"Eletreby R, Anees M, Naguib M, et al. The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents[J]. Expert Rev Gastroenterol Hepatol. 2021;15(1):103\u201310.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"1957_CR39","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/jgh3.12324","volume":"4","author":"R Nevola","year":"2020","unstructured":"Nevola R, Rinaldi L, Zeni L, et al. Metabolic and renal changes in patients with chronic Hepatitis C Infection after Hepatitis C virus clearance by direct-acting antivirals[J]. JGH Open. 2020;4(4):713\u201321.","journal-title":"JGH Open"},{"issue":"7","key":"1957_CR40","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/hepr.13666","volume":"51","author":"S Joshita","year":"2021","unstructured":"Joshita S, Yamashita Y, Okamoto T, et al. Quantitative and qualitative lipid improvement with chronic Hepatitis C virus eradication using direct-acting antivirals[J]. Hepatol Res. 2021;51(7):758\u201366.","journal-title":"Hepatol Res"},{"issue":"12","key":"1957_CR41","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1097\/MEG.0000000000001903","volume":"33","author":"M Abdo","year":"2021","unstructured":"Abdo M, Rabiee A, Abdellatif Z, et al. Impact of sustained virological response on metabolic disorders in diabetic chronic Hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir[J]. Eur J Gastroenterol Hepatol. 2021;33(12):1588\u201394.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"1957_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2169\/internalmedicine.5563-20","volume":"60","author":"N Hino","year":"2021","unstructured":"Hino N, Sasaki R, Takahashi Y, et al. Treatment of Hepatitis C Virus Infection with direct-acting Antiviral agents elevates the serum small-dense low-density lipoprotein cholesterol Level[J]. Intern Med. 2021;60(2):191\u20139.","journal-title":"Intern Med"},{"issue":"2","key":"1957_CR43","first-page":"534","volume":"15","author":"T Anca","year":"2023","unstructured":"Anca T, Tudor C, Robert N, et al. Changes in components of metabolic syndrome after antiviral eradication in Hepatitis C Virus Infection[J]. Life. 2023;15(2):534.","journal-title":"Life"},{"issue":"1","key":"1957_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s43162-023-00197-1","volume":"35","author":"Y Ahmed El, Tarek","year":"2023","unstructured":"Ahmed El, Tarek Y, Wesam I, et al. The efect of diferent direct antivirals on hepatic steatosis in nondiabetic and na\u00efve hepatitis Cinfected Egyptian patients [J]. Egypt J Intern Med. 2023;35(1):12.","journal-title":"Egypt J Intern Med"},{"key":"1957_CR45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2023.05.003","volume":"375","author":"C Diego","year":"2023","unstructured":"Diego C, Silvia E, Ana M, et al. Triglyceride-rich lipoproteins and insulin resistance in patients with chronic Hepatitis C receiving direct-acting antivirals [J]. Atherosclerosis. 2023;375:59\u201366.","journal-title":"Atherosclerosis"},{"issue":"9","key":"1957_CR46","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/ncb1631","volume":"9","author":"Y Miyanari","year":"2007","unstructured":"Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for Hepatitis C virus production[J]. Nat Cell Biol. 2007;9(9):1089\u201397.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1957_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1055\/s-0033-1358524","volume":"33","author":"EA Schaefer","year":"2013","unstructured":"Schaefer EA, Chung RT. HCV and host lipids: an intimate connection[J]. Semin Liver Dis. 2013;33(4):358\u201368.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"1957_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tem.2009.07.005","volume":"21","author":"GH Syed","year":"2010","unstructured":"Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism[J]. Trends Endocrinol Metab. 2010;21(1):33\u201340.","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"1957_CR49","first-page":"231","volume":"38","author":"GR Jimenez","year":"2014","unstructured":"Jimenez GR, Albacete RA, Monje AP, et al. [New Drugs in the treatment of chronic Hepatitis C][J]. Farm Hosp. 2014;38(3):231\u201347.","journal-title":"Farm Hosp"},{"issue":"4","key":"1957_CR50","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1053\/j.gastro.2018.11.022","volume":"156","author":"AA Butt","year":"2019","unstructured":"Butt AA, Yan P, Shuaib A, et al. Direct-acting antiviral therapy for HCV Infection is Associated with a reduced risk of Cardiovascular Disease Events[J]. Gastroenterology. 2019;156(4):987\u201396.","journal-title":"Gastroenterology"},{"issue":"7","key":"1957_CR51","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/jgh.14067","volume":"33","author":"LE Adinolfi","year":"2018","unstructured":"Adinolfi LE, Nevola R, Guerrera B, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic Hepatitis C patients[J]. J Gastroenterol Hepatol. 2018;33(7):1379\u201382.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"1957_CR52","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/lt.25351","volume":"24","author":"GA Roccaro","year":"2018","unstructured":"Roccaro GA, Mitrani R, Hwang WT, et al. Sustained virological response is Associated with a decreased risk of Posttransplant Diabetes Mellitus in Liver Transplant recipients with Hepatitis C-Related Liver Disease[J]. Liver Transpl. 2018;24(12):1665\u201372.","journal-title":"Liver Transpl"},{"key":"1957_CR53","doi-asserted-by":"crossref","unstructured":"Mauss S, Berger F, Wehmeyer MH, et al. Effect of antiviral therapy for HCV on lipid levels[J]. Antivir Ther. 2017;21(1):81\u201388.","DOI":"10.3851\/IMP3094"},{"issue":"1","key":"1957_CR54","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1038\/s41598-021-93251-3","volume":"11","author":"R Villani","year":"2021","unstructured":"Villani R, Di Cosimo F, Romano AD, et al. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis[J]. Sci Rep. 2021;11(1):13944.","journal-title":"Sci Rep"},{"issue":"1","key":"1957_CR55","first-page":"39","volume":"38","author":"A Jain","year":"2019","unstructured":"Jain A, Kalra BS, Srivastava S, Chawla S, et al. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic Hepatitis C, genotype 3 patients[J]. Gastroenterol. 2019;38(1):39\u201343.","journal-title":"Gastroenterol"},{"issue":"3","key":"1957_CR56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/cells8030252","volume":"8","author":"MA Doyle","year":"2019","unstructured":"Doyle MA, Galanakis C, Mulvihill E, et al. Hepatitis C direct acting antivirals and Ribavirin modify lipid but not glucose parameters. Cells. 2019;8(3):252\u20132.","journal-title":"Cells"},{"issue":"3","key":"1957_CR57","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/hep.27424","volume":"61","author":"EG Meissner","year":"2015","unstructured":"Meissner EG, Lee YJ, Osinusi A, et al. Effect of Sofosbuvir and Ribavirin treatment on peripheral and hepatic lipid metabolism in chronic Hepatitis C virus, genotype 1-infected patients. Hepatology. 2015;61(3):790\u2013801.","journal-title":"Hepatology"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01957-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-023-01957-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01957-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T11:02:48Z","timestamp":1709982168000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-023-01957-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1957"],"URL":"https:\/\/doi.org\/10.1186\/s12944-023-01957-2","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,9]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not require ethical approval because the meta analysis was based on published research and the original data wre anonymous.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"74"}}